ReviewCNS drug reviews2007
Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data.
Review in CNS drug reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 76 citations in OpenAlex.
- A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.Alcoholism, clinical and experimental research · 2012Trial
- Review
- SV2A expression in blood cells as a possible biomarker candidate for levetiracetam treatment response.Epilepsia · 2026Article
- Modelling dysfunction-specific interventions for seizure termination in epilepsy.NPJ systems biology and applications · 2025Article
- Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.Neuroscience bulletin · 2024Review
- Molecular Basic of Pharmacotherapy of Cytokine Imbalance as a Component of Intervertebral Disc Degeneration Treatment.International journal of molecular sciences · 2023Review
- Antiseizure Medications for the Prophylaxis of Migraine during the Anti- CGRP Drugs Era.Current neuropharmacology · 2023Review
- Levetiracetam ameliorates epileptogenesis by modulating the adenosinergic pathway in a kindling model of epilepsy in mice.Turkish journal of medical sciences · 2023Article
- Effectiveness of Antiseizure Medication Duotherapies in Patients With Glioma: A Multicenter Observational Cohort Study.Neurology · 2022Observational
- Impact of In Utero Exposure to Antiepileptic Drugs on Neonatal Brain Function.Cerebral cortex (New York, N.Y. : 1991) · 2022Article
- Connectivity Mapping Using a NovelFrontiers in molecular neuroscience · 2022Article
- Chronic levetiracetam (Keppra®) treatment increases the reinforcing strength of cocaine in rhesus monkeys.Pharmacology, biochemistry, and behavior · 2021Article
- Mechanisms of organophosphate neurotoxicity.Current opinion in toxicology · 2021Article
- Levetiracetam treatment leads to functional recovery after thoracic or cervical injuries of the spinal cord.NPJ Regenerative medicine · 2021Article
- Antiseizure Medication use in Gastric Bypass Patients and Other Post-Surgical Malabsorptive States.Epilepsy & behavior reports · 2021Review
- Age-Dependency of Levetiracetam Effects on Exocytotic GABA Release from Nerve Terminals in the Hippocampus and Cortex in Norm and After Perinatal Hypoxia.Cellular and molecular neurobiology · 2019Article
- Targeting Intracellular Calcium Stores Alleviates Neurological Morbidities in a DFP-Based Rat Model of Gulf War Illness.Toxicological sciences : an official journal of the Society of Toxicology · 2019Article
- Effects of levetiracetam on astroglial release of kynurenine-pathway metabolites.British journal of pharmacology · 2018Article
- Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition.British journal of pharmacology · 2017Review
- Mechanisms of levetiracetam in the control of status epilepticus and epilepsy.Frontiers in neurology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this article was to review and summarize the available reports on the preclinical profile of the novel anticonvulsant drug levetiracetam (LEV). Therefore, a careful search was conducted in the MEDLINE database and combined with guidelines from regulatory agencies, proceedings of professional scientific meetings, and information provided by the manufacturers. This article provides detailed information on the anticonvulsant effects of LEV in various animal models of epilepsy and on its pharmacology in laboratory animals. The mechanism of action of LEV is reviewed, with special regard to its recently discovered binding site, the synaptic vesicle protein 2A. In general, LEV is shown to be a safe, broad-spectrum anticonvulsant drug with highly beneficial pharmacokinetic properties and a distinct mechanism of action. The clinical studies with LEV will be discussed in the second part of this review article to be published subsequently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.